0001477932-26-002727
SEC filingChallenging development-stage year defined by minimal operations and persistent going concern risks, as auditors highlighted substantial cumulative losses and dependence on uncertain future financing amid a post-year-end strategic pivot to AI healthcare.
Catalyst Crew Technologies remained in a quiescent development stage throughout FY2025, generating no revenue as its current AI healthcare focus crystallized only after year-end. Management's discussion confirms limited operations, with the strategic shift to CardioAI, PulmoAI, and NeuroAI platforms occurring via a February 2026 asset purchase from the incoming CEO amid a change in control. This timing explains the absence of topline activity and positions 2025 results as a transitional baseline rather than indicative of the new direction's potential.
Auditors raised substantial doubt about the company's ability to continue as a going concern, citing accumulated losses and reliance on future financing that may not be available. This reflects ongoing liquidity challenges in a minimal-operation phase, where the company lacks assets to support working capital needs and depends entirely on external capital inflows for survival. The emphasis underscores the precarious financial position, necessitating immediate funding to bridge to operational ramp-up.
Post-2025 catalysts include the February 2026 control shift to Dr. Kevin Rodan Levy, who sold IP for the AI platform and services model targeting Latin America via Venezuelan subsidiary Inversiones Long 33, C.A. Acquired in March 2026 and assigned IP in April, this entity introduces economic instability, currency controls, and IP enforcement risks in a high-uncertainty jurisdiction. With no employees as of year-end and reliance on the CEO—who holds majority voting power—the execution depends on his divided time and external funding.
Entering the AI healthcare space post-year-end amplifies competitive, regulatory, and technological risks. The platforms target underserved Latin American markets but face validation hurdles, integration challenges with existing systems, and unproven efficacy in real-world settings. No commercial agreements exist, heightening execution uncertainty in a sector demanding rapid innovation and capital-intensive development.
Advancement requires capital for development, regulatory compliance, and market entry in Venezuela-focused Latin America. Success pivots on financing availability, technology efficacy, and navigating geopolitical risks—watch for funding announcements and subsidiary progress as primary catalysts. The going concern qualification signals to investors the critical need for near-term capital raises to sustain operations through the pivot.